General MedicationsSUBCUTANEOUSGeneric
SYMLIN
PRAMLINTIDE ACETATE
Standard Dose
EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview SYMLIN is listed in Drugs@FDA under application 021332 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient PRAMLINTIDE ACETATE Form and strength INJECTABLE;SUBCUTANEOUS - EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2019-12-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview SYMLIN is listed in Drugs@FDA under application 021332 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PRAMLINTIDE ACETATE Form and strength INJECTABLE;SUBCUTANEOUS - EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2019-12-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.